XRAY vs. NVST, EXEL, ACHC, GRFS, NTRA, CTLT, EHC, THC, SWAV, and BRBR
Should you be buying DENTSPLY SIRONA stock or one of its competitors? The main competitors of DENTSPLY SIRONA include Envista (NVST), Exelixis (EXEL), Acadia Healthcare (ACHC), Grifols (GRFS), Natera (NTRA), Catalent (CTLT), Encompass Health (EHC), Tenet Healthcare (THC), Shockwave Medical (SWAV), and BellRing Brands (BRBR). These companies are all part of the "medical" sector.
Envista (NYSE:NVST) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.
In the previous week, DENTSPLY SIRONA had 7 more articles in the media than Envista. MarketBeat recorded 7 mentions for DENTSPLY SIRONA and 0 mentions for Envista. Envista's average media sentiment score of 0.60 beat DENTSPLY SIRONA's score of 0.00 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.
Envista has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 1.2% of Envista shares are owned by insiders. Comparatively, 0.8% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Envista currently has a consensus price target of $34.63, suggesting a potential upside of 47.59%. DENTSPLY SIRONA has a consensus price target of $38.89, suggesting a potential upside of 21.99%. Given DENTSPLY SIRONA's higher probable upside, equities research analysts clearly believe Envista is more favorable than DENTSPLY SIRONA.
Envista has higher earnings, but lower revenue than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
Envista has a net margin of 7.39% compared to Envista's net margin of -5.44%. Envista's return on equity of 10.91% beat DENTSPLY SIRONA's return on equity.
DENTSPLY SIRONA received 418 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.13% of users gave DENTSPLY SIRONA an outperform vote while only 45.76% of users gave Envista an outperform vote.
Summary
DENTSPLY SIRONA beats Envista on 9 of the 16 factors compared between the two stocks.
Get DENTSPLY SIRONA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DENTSPLY SIRONA Competitors List
Related Companies and Tools
